Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia

• Status: Terminated
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main aim of the investigation is to clarify, whether vitamin D supplementation in coronary artery disease patients with vitamin D deficiency and postchallenge hyperglycemia has an impact on endothelial dysfunction and parameters of insulin sensitivity and beta-cell function.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Graz
• Treatments: Ergocalciferols; Insulin; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Age 40-75

• Postchallenge hyperglycemia (2h-whole blood glucose value in oral glucose tolerance test above 119 mg/dl, normal fasting glucose)

• Angiographically verified coronary artery disease (>50% stenosis)

• Serum 25-OH- vitamin D < 20 ng/ml in winter/spring/autumn and <25 ng/ml during june-september

• Stable antihypertensive therapy in the last 3 month

Exclusion Criteria:

• Acute coronary syndrome or cerebrovascular event within the previous 1 month

• BMI > 40 kg/m²

• Serum creatinine >2.5 times the upper limit of normal

• GOT or GPT > 3 times the upper limit of normal

• Heart failure > NYHA class II

• Uncontrolled hypertension (>160/100 mmHg)

• New onset of statins, ACE-inhibitors or ARBs within the previous 4 weeks

• History of urolithiasis

• Hypercalcaemia

• Major psychiatric disorders

• Ongoing treatment with spironolactone, canrenoate, eplerenone, amiloride, triamterene and aliskiren.

• Treatment with antipsychotic drugs

• Regular significant antioxidants, vitamins or protein supplementation

• Immunosuppressive therapy

• Glucocorticoid therapy

• Ongoing chemotherapy

• Pregnancy

• Any other disease with an estimated life expectancy below 1 year.